TRML vs. REPL, LXEO, VYGR, ITOS, TSHA, AURA, HUMA, ADPT, CRBU, and EDIT
Should you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include Replimune Group (REPL), Lexeo Therapeutics (LXEO), Voyager Therapeutics (VYGR), iTeos Therapeutics (ITOS), Taysha Gene Therapies (TSHA), Aura Biosciences (AURA), Humacyte (HUMA), Adaptive Biotechnologies (ADPT), Caribou Biosciences (CRBU), and Editas Medicine (EDIT). These companies are all part of the "biological products, except diagnostic" industry.
Tourmaline Bio (NASDAQ:TRML) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, community ranking, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.
Tourmaline Bio has a beta of 2.33, indicating that its stock price is 133% more volatile than the S&P 500. Comparatively, Replimune Group has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500.
91.9% of Tourmaline Bio shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 16.5% of Tourmaline Bio shares are held by company insiders. Comparatively, 20.6% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Tourmaline Bio's return on equity of -30.86% beat Replimune Group's return on equity.
Replimune Group received 143 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 61.54% of users gave Replimune Group an outperform vote.
Tourmaline Bio presently has a consensus price target of $61.80, indicating a potential upside of 294.13%. Replimune Group has a consensus price target of $37.67, indicating a potential upside of 486.71%. Given Replimune Group's higher probable upside, analysts clearly believe Replimune Group is more favorable than Tourmaline Bio.
Replimune Group is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Tourmaline Bio had 2 more articles in the media than Replimune Group. MarketBeat recorded 2 mentions for Tourmaline Bio and 0 mentions for Replimune Group. Tourmaline Bio's average media sentiment score of 0.40 beat Replimune Group's score of 0.00 indicating that Tourmaline Bio is being referred to more favorably in the media.
Summary
Tourmaline Bio beats Replimune Group on 9 of the 14 factors compared between the two stocks.
Get Tourmaline Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tourmaline Bio Competitors List
Related Companies and Tools
